National Institute on Drug Abuse (NIDA)

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, National Institute on Drug Abuse (NIDA) sits in the top decile of US sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count).

335 total trials 14 currently recruiting 292 completed early-phase tilt top decile by trial count

National Institute on Drug Abuse (NIDA): 335 sponsored US clinical trials, 14 recruiting.

National Institute on Drug Abuse (NIDA) sponsors 335 registered US clinical trials on ClinicalTrials.gov, 14 of them currently recruiting, and 292 completed. 30 of these trials are in Phase 3-4 (later-stage) and 202 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cocaine-Related Disorders, with 17 trials.

Top-decile sponsor footprint

National Institute on Drug Abuse (NIDA) ranks in the top decile of sponsors by registered trial count (#108 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 71/100

292 of 316 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

335 total, page 1 of 7

RECRUITING Phase 1

Environment and Alcohol: A Pilot Study

NCT06860607
RECRUITING Early Phase 1

Developing Transcranial Neuromodulation Protocols for Learning and Decision-Making

NCT06561828
RECRUITING

SMART-r: Substance Monitoring and Active Relapse Tracking Repository

NCT06676059
RECRUITING

Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP

NCT06552741
RECRUITING Phase 3

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
RECRUITING Phase 2

Semaglutide Therapy for Alcohol Reduction (STAR)

NCT06015893
RECRUITING Phase 1

Spironolactone in Alcohol Use Disorder (SAUD)

NCT05807139
RECRUITING

Development and Validation of Learning and Decision-Making Tasks

NCT05707806
RECRUITING NA

Orexin s Role in the Neurobiology of Substance Use Disorder

NCT05630781
RECRUITING NA

Defining Neurobiological Links Between Substance Use and Mental Illness

NCT05538910
RECRUITING Phase 1

Evaluation of the Interactions of Cannabidiol (CBD) With Morphine

NCT05143424
RECRUITING

Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder

NCT03745339
RECRUITING NA

Mechanism of Non-invasive Magnetic Stimulation

NCT03394066
RECRUITING NA

Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

NCT01036581
NOT YET RECRUITING Phase 1

Phase 1 Study of Oral MG001

NCT07204171
NOT YET RECRUITING Phase 1

VK4-116 Phase I Study With Food-Effect

NCT06808932
NOT YET RECRUITING

Olfactory Function and Model-Based Behavior in People Living With HIV and SUD

NCT07637669
NOT YET RECRUITING Early Phase 1

Causal Mechanisms of Odor-Guided Behavior in Humans

NCT07099092
NOT YET RECRUITING Phase 1

Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)

NCT06868914
TERMINATED NA

Hippocampal Network Changes Following Mindfulness Training in Tobacco Vaping Adolescents in an Open-label, Pilot Study

NCT06503159
COMPLETED Phase 1

SXC-2023 Cocaine Interaction Study

NCT06343532
TERMINATED

Adolescent Vaping Characterization and Parent Views on Adolescent Vaping Protocol

NCT05669716
COMPLETED

Real-world Momentary Assessment of Kratom Use Accompanied by Product Assays: A Natural-history Study for Interdisciplinary Characterization of Kratom Use and Pharmacology

NCT05457803
TERMINATED Phase 2

Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD

NCT04316559
COMPLETED Phase 1

Manipulating Ghrelin Signaling Via GOAT Inhibition in Alcohol Use Disorder

NCT03896516
TERMINATED NA

Just-In-Time Adaptive Interventions for Addictive Behaviors

NCT03538652
TERMINATED

Imaging Biomarker for Addiction Treatment Outcome

NCT03427424
COMPLETED Phase 1

Comparison of Naloxone Pharmacokinetics

NCT03386591
COMPLETED Phase 2

Lorcaserin in the Treatment of Cocaine Use Disorder

NCT03007394
COMPLETED Phase 1

Evaluation of the Effects of Cannabidiol (CBD) Compared to Delta-9-Tetrahydrocannabinol (THC) and Alprazolam

NCT03398083
COMPLETED

Exploring Gut-Brain and Brain-Gut Interactions in Alcohol Use Disorder Via Microbiota Investigations: A Pilot Study

NCT03152760
COMPLETED Phase 1

Pharmacokinetic Evaluation of Nalmefene Administered Intranasally to Healthy Volunteers

NCT03129347
COMPLETED NA

Effects of a New Behavioral Intervention on Alcohol Craving and Drinking

NCT02831049
TERMINATED NA

Theta-Burst Stimulation as a Treatment for Reducing Cocaine Use

NCT02927236
COMPLETED Phase 1

Pharmacokinetic Evaluation of Intranasal, Intramuscular, and Oral Naltrexone in Healthy Volunteers

NCT02750748
COMPLETED Phase 2

The Study of AZD8529 for Smoking Cessation in Female Smokers

NCT02401022
COMPLETED Phase 1

Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin

NCT02393599
COMPLETED Phase 1

Pharmacokinetic Evaluation of Intranasal and Intramuscular Naloxone in Healthy Volunteers

NCT02572089
COMPLETED NA

Repetitive Transcranial Magnetic Stimulation Equipment Testing and Pilot Study

NCT02231892
COMPLETED

Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African Americans

NCT02225184
COMPLETED Phase 1

Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics

NCT02177513
COMPLETED

Multimodal Neuroimaging Genetic Biomarkers of Nicotine AddictionSeverity

NCT01867411
COMPLETED Phase 1

Brain Networks and Addiction Susceptibility

NCT01924468
COMPLETED NA

Nicotine Withdrawal Symptoms and Smoking Relapse

NCT01511614
COMPLETED Phase 2

Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana

NCT01844687
COMPLETED Phase 2

A Multi-Center Trial of Nepicastat for Cocaine Dependence

NCT01704196
COMPLETED NA

Three Strategies for Implementing Motivational Interviewing on Medical Inpatient Units

NCT01825057
COMPLETED Phase 1

Interactions Between Intravenous Cocaine and Acetazolamide or Quinine

NCT01851473
COMPLETED

Studying Nicotine Addiction With Transcranial Magnetic Stimulation

NCT01702948
COMPLETED Phase 1

Factors Affecting Methamphetamine and Opiates Drug Testing

NCT01736332
Page 1 of 7 Next →

Phase Distribution

PhaseTrial count
Phase 1 81
Phase 2 121
Phase 3 14
Phase 4 16

Therapeutic Areas

Cocaine-Related Disorders 17
Opioid-Related Disorders 10
Substance-Related Disorders 10
Nicotine Dependence 8
Tobacco Use Disorder 7
Heroin Dependence 5
Alcohol Use Disorder 4
Normal Physiology 3
Drug Abuse 2
Amphetamine-Related Disorders 2

What is open in the National Institute on Drug Abuse (NIDA) pipeline

14 recruiting of 335 indexed (4% open); 292 completed (87%).

Phase mix: 30 late (III/IV) vs 202 early (I/II) (early-phase heavy).

Top condition: Cocaine-Related Disorders (17 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

National Institute on Drug Abuse (NIDA): open-pipeline peers nationwide

Peers matched on 335 registered trials and 4% open enrollment, not the therapeutic-area sidebar.

National Institute on Drug Abuse (NIDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400 0%5%10%15%20%25% Total trials Recruiting share National Institute on Drug Abuse (NIDA)BiogenNational Institutes of Health Clinical Center (CC)GenentechCedars-Sinai Medical CenterAkebia TherapeuticsDentsply Sirona Implants and ConsumablesSmith & NephewMedtronic - MITG
National Institute on Drug Abuse (NIDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

National Institute on Drug Abuse (NIDA) sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 335 trials (± recruiting share)

Sponsors near 4% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this National Institute on Drug Abuse (NIDA) page

335 registered trials is a research-attention snapshot, not an endorsement of National Institute on Drug Abuse (NIDA) or any single study.

  • 14 of National Institute on Drug Abuse (NIDA)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cocaine-Related Disorders is the condition National Institute on Drug Abuse (NIDA) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cocaine-Related Disorders trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

National Institute on Drug Abuse (NIDA) pipeline card: 335 registered trials from official public datasets.Report a data error.